Institution

Ghent University Hospital

Ghent, BelgiumWebsite

Also known as: UZ Gent · Universitair Ziekenhuis Gent

631running trials
294closed trials
36,671publications (OpenAlex)

Running trials

Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Nationwide Children's Hospital· Source
Not yet recruiting
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source
Not yet recruiting
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· Phase 3· Boehringer Ingelheim· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Recruiting
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
NCT07773727· Phase 2· argenx· Source
Recruiting
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895· Phase 1/2· Boehringer Ingelheim· Source
Not yet recruiting
AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
NCT07883551· Catharina Ziekenhuis Eindhoven· Source
Recruiting
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
NCT07444450· Phase 3· Biogen· Source
Recruiting
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
NCT07357675· Phase 3· EBI Anti Sepsis BV· Source
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospital Stay Following On-Pump Coronary Artery Bypass Grafting Surgery
2025-525053-39-00· Phase 3· EBI Anti Sepsis B.V.· Source
Not yet recruiting
A Phase 1/2/3 Study of ATSN-201 Gene Therapy in Subjects with RS1-Associated X linked Retinoschisis
NCT05878860· Phase 3· Atsena Therapeutics Inc.· Source
Recruiting
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
NCT07700758· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Recruiting
A clinical trial of MK-3586 in healthy participants (MK-3586-001)
2026-527250-39-00· Phase 1· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
NCT07843940· Phase 1/2· Boehringer Ingelheim· Source
Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source
Recruiting
ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole
2025-524995-53-00· Phase 4· UZ Brussel· Source
Recruiting
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200· Phase 2· NS Pharma, Inc.· Source
Recruiting
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
2025-521164-36-00· Phase 1/2· Apmonia Therapeutics· Source
Recruiting
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
NCT07753148· Phase 1· Regeneron Pharmaceuticals· Source
Recruiting
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
NCT07759167· Phase 1· Regeneron Pharmaceuticals· Source
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264· Phase 3· CSL Behring· Source
Recruiting
Identification of Changes in Cancer-related Fatigue and Physical Activity and Their Association in Patients With Inoperable Lung Cancer: a Longitudinal Observational Study
NCT07799974· University Hospital, Ghent· Source
Recruiting
Natural History Study of Advanced RCD
NCT07854899· SparingVision· Source
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Recruiting
Optimizing Gait Rehabilitation After Stroke
NCT07798388· University Hospital, Ghent· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Charite University, Berlin, Germany· Source
Not yet recruiting
Phase 2 Trial of TAK-755 for Acute Ischemic Stroke
2025-522734-31-00· Phase 2· Takeda Development Center Americas Inc.· Source
Not yet recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
2026-526419-13-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
NCT07630714· Phase 2· AstraZeneca· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-524711-36-00· Phase 3· Alkermes Inc.· Source
Recruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· Phase 1/2· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source
Not yet recruiting
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
NCT07760818· Phase 2· argenx· Source
Recruiting
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials
2024-519638-22-00· Phase 3· Novartis Pharma AG· Source
Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study Comparing an Investigational Wound Gel With Standard Treatment for Mild to Moderate Diabetic Foot Ulcers
NCT07783087· Flen Health· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
2025-523912-35-00· Phase 3· Alkermes Inc.· Source
Not yet recruiting
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
NCT07682129· Phase 2· Entrada Therapeutics, Inc.· Source
Recruiting
Short Term Effects of a Multimodal Intervention With RGM on Cognition in People With Parkinson's Disease.
NCT07863219· University Ghent· Source
Not yet recruiting
Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy
2025-523575-36-00· Phase 2· Cliniques Universitaires Saint-Luc· Source
Recruiting
F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of Survival
2023-508709-26-00· Phase 2· Universitair Ziekenhuis Gent· Source

Showing 50 of 631.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers44 recruiting
Lung cancer29 recruiting
Colorectal cancer20 recruiting
Prostate cancer19 recruiting
Crohn's disease18 recruiting
Gastric and oesophageal cancer17 recruiting
Acute myeloid leukaemia16 recruiting
Pancreatic cancer15 recruiting
Multiple myeloma13 recruiting
Stroke13 recruiting
Ovarian cancer12 recruiting
Liver and biliary tract cancer11 recruiting
Acute lymphoblastic leukaemia10 recruiting
Ulcerative colitis9 recruiting
Bladder cancer8 recruiting
Chronic lymphocytic leukaemia8 recruiting
Head and neck cancer8 recruiting
Endometrial cancer7 recruiting
Fatty liver disease (MASLD/MASH)7 recruiting
Melanoma7 recruiting
Metastatic breast cancer7 recruiting
Psoriasis7 recruiting
Heart failure6 recruiting
HIV6 recruiting
Kidney cancer6 recruiting
Narcolepsy6 recruiting
Triple-negative breast cancer6 recruiting
Cervical cancer5 recruiting
Chronic myeloid leukaemia5 recruiting
Lupus (SLE)5 recruiting
Obesity5 recruiting
Psoriatic arthritis5 recruiting
Ankylosing spondylitis4 recruiting
Aortic aneurysm4 recruiting
Coronary artery disease4 recruiting
Duchenne muscular dystrophy4 recruiting
Epilepsy4 recruiting
High blood pressure4 recruiting
Myelodysplastic syndromes4 recruiting
Primary biliary cholangitis4 recruiting
Rheumatoid arthritis4 recruiting
Sarcoma4 recruiting
Sjögren's disease4 recruiting
Asthma3 recruiting
Barrett's oesophagus3 recruiting
Chronic rhinosinusitis with nasal polyps3 recruiting
Diffuse large B-cell lymphoma3 recruiting
Glioblastoma3 recruiting
Liver cirrhosis3 recruiting
Myeloproliferative neoplasms3 recruiting
Osteoarthritis3 recruiting
Retinitis pigmentosa3 recruiting
Spinal muscular atrophy3 recruiting
Systemic sclerosis (scleroderma)3 recruiting
Alzheimer disease2 recruiting
Amyloidosis2 recruiting
Bronchiectasis2 recruiting
Chronic kidney disease2 recruiting
COPD2 recruiting
Dermatomyositis and polymyositis (myositis)2 recruiting
Hidradenitis suppurativa2 recruiting
Hodgkin lymphoma2 recruiting
IgA nephropathy2 recruiting
Irritable bowel syndrome2 recruiting
Mitochondrial disease2 recruiting
Multiple sclerosis2 recruiting
Myasthenia gravis2 recruiting
Neuroblastoma2 recruiting
Neuroendocrine tumours2 recruiting
Parkinson disease2 recruiting
Peripheral artery disease2 recruiting
Pulmonary arterial hypertension2 recruiting
Spinal cord injury2 recruiting
Turner syndrome2 recruiting
Type 1 diabetes2 recruiting
Type 2 diabetes2 recruiting
Vitiligo2 recruiting
Atopic dermatitis (eczema)1 recruiting
Brain aneurysm1 recruiting
Brain metastases1 recruiting
Burkitt lymphoma1 recruiting
Cerebral palsy1 recruiting
Chronic spontaneous urticaria1 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
Cystic fibrosis1 recruiting
Cytomegalovirus infection1 recruiting
Diabetic foot ulcer1 recruiting
Endometriosis1 recruiting
Follicular lymphoma1 recruiting
Gestational diabetes1 recruiting
Graves' disease1 recruiting
Hearing loss1 recruiting
Idiopathic pulmonary fibrosis1 recruiting
Lewy body dementia1 recruiting
Macular degeneration1 recruiting
Meningioma1 recruiting
Mesothelioma1 recruiting
Myotonic dystrophy1 recruiting
Osteoporosis1 recruiting
Pituitary tumours1 recruiting
Polycystic kidney disease1 recruiting
Testicular cancer1 recruiting
Thyroid cancer1 recruiting

Closed trials

Completed
A Trial to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy.
2025-523503-30-00· Phase 2· Eisai Limited· Source
Terminated
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
NCT06595563· Phase 2· Jules Bordet Institute· Source
Active, not recruiting
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.
2023-503298-39-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
2025-524230-25-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Completed
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis
NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Withdrawn
Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)
NCT07237399· University Hospital, Ghent· Source
Active, not recruiting
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
NCT07424144· Phase 3· Sanofi· Source
Completed
A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)
2025-524852-74-00· Phase 1· Merck Sharp & Dohme LLC· Source
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
Evaluation of the CochSyn Device in Clinical Practice
NCT07091071· University Ghent· Source
Completed
Communication Training in Hearing Aid Users
NCT07798453· University Ghent· Source
Recruiting
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· Phase 2· CSL Behring· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis
NCT06867094· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults
NCT06989788· Phase 1· AstriVax Therapeutics· Source
Completed
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)
NCT06684847· Phase 3· Argenx· Source
Completed
A clinical study of MK-2420 in healthy people (MK-2420-002)
2024-516548-25-00· Phase 1· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483· Phase 2· BicycleTx Limited· Source
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· Phase 2· Amgen· Source
Completed
A clinical study of MK-2420 in healthy men (MK-2420-003)
2024-518104-47-00· Phase 1· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
NCT07667322· Phase 1· Hoffmann-La Roche· Source
Completed
A clinical study of MK-4646 in healthy people (MK-4646-002)
2024-516626-63-00· Phase 1· Merck Sharp & Dohme LLC· Source
Completed
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE
NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Active, not recruiting
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
NCT06321601· Phase 3· Amgen· Source
Completed
A Study of TAK-861 in People With Narcolepsy Type 1
NCT06505031· Phase 3· Takeda· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Completed
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source
Active, not recruiting
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197· Phase 2· AstraZeneca· Source
Completed
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
NCT06522997· Phase 2· Bayer· Source
Completed
A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl
NCT06340802· Synergia Medical· Source
Completed
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome
2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source
Completed
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction
2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )
NCT06341712· Phase 2· Ipsen Innovation· Source
Completed
MK-4646 Single Ascending Dose Study and DDI in Healthy Participants
2024-510899-20-00· Phase 1· Merck Sharp & Dohme LLC· Source
Completed
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Completed
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
NCT05870748· Phase 2· Sutro Biopharma Inc.· Source
Completed
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT06395753· Phase 2· Debiopharm International SA· Source
Completed
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
NCT06333860· Phase 4· AbbVie· Source
Completed
MK-2420 SAD Study
2024-511297-73-00· Phase 1· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Erasca, Inc.· Source
Completed
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· Phase 3· Incyte Corporation· Source
Completed
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
NCT05865886· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875· Phase 2· AbbVie· Source
Completed
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
NCT06168409· Phase 3· AstraZeneca· Source
Completed
Dynamic Ultrasound of the Calf Muscles After Stroke
NCT06250478· University Hospital, Ghent· Source
Completed
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
2022-502453-33-00· Phase 2· Genmab A/S· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· Phase 3· Amgen· Source
Recruiting
A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.
NCT06230224· Phase 3· Regeneron Pharmaceuticals Inc.· Source
Completed
A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain
2022-501310-57-00· Phase 2· Organon LLC· Source
Active, not recruiting
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999· Phase 3· Incyte Corporation· Source

Showing 50 of 294.

Registry name variants (116)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Universitair Ziekenhuis Gent
Gent, 9000
597 trials
UZ Gent
Ghent, 9000
100 trials
Universitair Ziekenhuis Gent
Ghent, 9000
70 trials
Ghent university hospital
Ghent, 9000
59 trials
University Hospital Ghent
Ghent, 9000
30 trials
Universitair Ziekenhuis Gent (Uz Gent)
Ghent, 09000
9 trials
UZ Gent
Gent, 9000
9 trials
UZ GENT (Universitair Ziekenhuis Gent)
Ghent, 9000
4 trials
Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
Ghent, Oost-Vlaanderen 9000
3 trials
- NCT07759167Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
  Contact: Clinical Trials Administrator
- NCT06091865A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
  Contact: Clinical Trials Administrator
- NCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
  Contact: Clinical Trials Administrator
University Hospital of Ghent
Ghent, 9000
3 trials
- NCT05678218Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
- NCT04083612Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients
- NCT01281735International Chronic Myeloid Leukemia Pediatric Study
  Contact: Barbara DE MOERLOOSE, Prof.
Department of Gastroenterology and Hepatology Universitair Ziekenhuis Gent
Ghent, Belgium
2 trials
- NCT06723275LEOPARD Prospective Validation Cohort 1
  Contact: Xavier Verhelst, MD-PHD
- NCT06675604LEOPARD Training and Validation Data Collection Study
  Contact: Hasan Eker, MD-PHD
Ghent University Hospital
2 trials
- NCT05878860A Phase 1/2/3 Study of ATSN-201 Gene Therapy in Subjects with RS1-Associated X linked Retinoschisis
- NCT06454188A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Ghent University Hospital (UZ Gent)
Ghent, Belgium 9000
2 trials
- NCT07455422A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer
  Contact: David Tate
- NCT04005976Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease
  Contact: Julie DeBacker, MD
University Hospital Ghent (UZ Gent), Belgium
Ghent, Oost-Vlaanderen 9000
2 trials
- NCT07798388Optimizing Gait Rehabilitation After Stroke
  Contact: Gitte Van Cleemput
- NCT07494630Joint Endoprostheses Can Succesfully Treat Disabling Osteoarthritis. However, Infection is an Important Cause of Failure. Adequate Diagnostics Remains Challenging. Combining Advanced Imaging With Next-generation Sequencing of Samples Obtained Endoscopically Should Aid in Mapping and Characterizing.
UZ Gent - Department Gastro-enterology
Ghent, 9000
2 trials
- NCT05016882Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
- NCT04822181Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
UZ Gent - Endocrinologie - Diabetologie
Ghent, 9000
2 trials
- NCT03914326A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
- NCT03819153A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
0560037 - Universitair Ziekenhuis Gent
Ghent, 9000
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Department of Neurology - Ghent University Hospital
Ghent, Flanders 9000
1 trial
- NCT04956185Data Collection of Patients Admitted to the Stroke Unit
  Contact: Veerle De Herdt, MD, PhD
Department of Pediatric Hematology, Oncology and SCT, Ghent University Hospital
Ghent, 9000
1 trial
- NCT05477589Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
  Contact: Victoria Bordon, MD, PhD
Dept of Radiotherapy, University Hospital Ghent
Ghent, 9000
1 trial
- NCT02397434Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer
Ghent University Hospital
Gent, 9000
1 trial
- NCT06571149Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
Ghent University Hospital, Dept. of Endocrinology
Ghent, 9000
1 trial
- NCT0499348224-hour Movement Behaviors Among Type 2 Diabetes Mellitus Patients
  Contact: Bruno Lapauw, MD, PhD
Ghent University Hospital, Dept. Radiotherapy-Oncology
Ghent, 9000
1 trial
- NCT03121248Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years
Universitair Ziekenhuis Gent (Belgium,Ghent)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT07392450A Study of TAK-755 in Adults With Acute Ischemic Stroke
  Contact: Dimitri Hemelsoet (principal investigator)
Universitair Ziekenhuis Gent - Medical Oncology
Ghent
1 trial
- NCT05327530A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie
Ghent, 9000
1 trial
- NCT06284122Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Universitair Ziekenhuis Gent, Thoracale en vasculaire heelkunde
Ghent, 9000
1 trial
- NCT04503395ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
  Contact: Isabelle vanHerzeele
Universitair Ziekenhuis Gent (UZ)
Ghent, 9000
1 trial
- NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
University Hospital, Ghent: Department of Neurology
Ghent, 9000
1 trial
- NCT05153876An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
University Hospitals Ghent
Ghent
1 trial
- NCT05727605Neurocognition After Radiotherapy in CNS- and Skull-base Tumors
  Contact: Tom Boterberg, MD PhD
UZ Gent - department of otorhinolaryngology
Ghent, 9000
1 trial
- NCT06114680Evaluation of the CochSyn Test Prototype to Measure Cochlear Synaptopathy
UZ Gent - Digestive Oncology
Ghent, Oost-Vlaaanderen 9000
1 trial
- NCT07811193A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
UZ Gent_Gent_1
Ghent, 9000
1 trial
- NCT04560998A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
UZ Gent /ID# 127985
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
UZ Gent /ID# 154296
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
UZ Gent /ID# 164210
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT03104374A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
UZ Gent /ID# 220841
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
UZ Gent /ID# 221125
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
UZ Gent /ID# 246462
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT05618028Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
UZ Gent /ID# 252458
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT05959070An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
UZ Gent /ID# 268630
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT06581042Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
  Contact: Liesbeth Ghys
UZ Gent /ID# 269737
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT05041257Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
UZ Gent /ID# 279433
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT07382440A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
  Contact: Clementine Semanaz
UZ Gent - pediatrics
Ghent, 9000
1 trial
- NCT04414280The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMs
UZ Gent (Site 0101)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT04456699Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
UZ Gent (Site 0163)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
UZ Gent (Site 0203)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
UZ Gent (Site 0250)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT04447755A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
UZ Gent (Site 0300)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
UZ Gent (Site 0375)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
UZ Gent (Site 0650)
Ghent, 9000
1 trial
- NCT03040999Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
UZ Gent (Site 1002)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT04662710Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
UZ Gent (Site 1100)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
UZ Gent (Site 3101)
Ghent, Oost-Vlaanderen 9000
1 trial
- NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  Contact: Study Coordinator
UZ Gent - Thoracale Vasculaire Heelkunde
Ghent, 9000
1 trial
- NCT04560998A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
Ghent University Hospital
Gent (Ghent), 9000
Universitair Ziekenhuis Gent - Gastro IBD
Ghent, 9000
Universitair Ziekenhuis Gent - Medische Oncologie
Ghent, 9000
Universitair Ziekenhuis Gent, Neuromuscular Reference Centre (NMRC)
Ghent, East Flanders 9000
Universitair Ziekenhuis Gent (Site 2037)
Ghent, Oost-Vlaanderen 9000
Universitair Ziekenhuis Gent - UZG
Ghent, 9000
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)
Ghent
University Hospital Ghent (UZ Ghent)
Ghent, 9000
UZ Gent
Gent Oost-Vlaanderen, 9000
UZ Gent - departement oncologie
Ghent, 9000
UZ Gent - department Urology
Ghent, East Flanders 9000
UZ Gent - Endocrinologie
Ghent, 9000
UZ Gent /ID# 142859
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 153392
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 157405
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 202030
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 202778
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 205181
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 210037
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 215004
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 218767
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 223899
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 246957
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 248605
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 250031
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 252306
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 254090
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 257083
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 257317
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 258210
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 259430
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 260312
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 261300
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 263099
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 263107
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 269309
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 271432
Ghent, Oost-Vlaanderen 9000
UZ Gent /ID# 273244
Ghent, Oost-Vlaanderen 9000
UZ Gent / Nephrology
Ghent, 9000
UZ Gent - Neurologie
Ghent, 9000
UZ Gent - Pediatric Cardiology
Ghent, East Flanders 9000
UZ Gent (Site 0031)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0064)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0224)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0255)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0301)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0307)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0406)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0486)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0602)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0604)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 0702)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 1201)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 1428)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 2004)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 3202)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 3403)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 3428)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 4401)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 4428)
Ghent, Oost-Vlaanderen 9000
UZ Gent (Site 5428)
Ghent, Oost-Vlaanderen 9000

Conditions

Diseases this institution publishes on or runs trials for.

Asthma54 works · 8 trials
COPD29 works · 6 trials
Psoriasis24 works · 22 trials
Crohn's disease23 works · 33 trials
Systemic sclerosis (scleroderma)22 works · 11 trials
Ankylosing spondylitis18 works · 8 trials
Chronic rhinosinusitis with nasal polyps16 works · 7 trials
Cystic fibrosis15 works · 7 trials
Endometrial cancer14 works · 15 trials
Vitiligo13 works · 7 trials
Psoriatic arthritis11 works · 12 trials
Antiphospholipid syndrome10 works · 0 trials
Neuroblastoma9 works · 5 trials
Retinitis pigmentosa6 works · 6 trials
Myasthenia gravis6 works · 3 trials
Eosinophilic oesophagitis4 works · 0 trials
Polymyalgia rheumatica3 works · 0 trials
Testicular cancer3 works · 1 trial
Turner syndrome3 works · 2 trials

Institution data: ROR 00xmkp704 (CC0-1.0)Updated 14 Nov 2026

Report an error